Cross-presentation is important for initiating CTL responses against tumors. Delivery of exogenous Ags to the cross-presentation pathway in dendritic cells (DCs), using a number of different carriers, has been attempted to further understand the mechanisms underlying cross-presentation and to develop therapeutic tumor vaccines. The present study reports a new antigenic carrier molecule: a single-chain V region fragment (scFv) of a nucleic acid-hydrolyzing Ab, 3D8. A fusion protein comprising 3D8 scFv and the CTL epitope OVA 250-264 (chicken OVA aa 250-264) was internalized by DC2.4 DCs and processed via a proteasome-dependent, brefeldin-and cycloheximide-sensitive, chloroquine-and primaquine-insensitive pathway, resulting in loading of the CTL epitope onto H-2K b . In vivo cross-presentation and cross-priming were efficient, even without adjuvant; injection of mice with 3D8 scFv-OVA 250-264 induced cross-presentation of the CTL epitope by draining lymph node CD11c + B7. A ntigens captured from the extracellular environment by APCs are processed and then presented on MHC class I molecules to CD8 + CTLs in a process called "cross-presentation," resulting in the stimulation of CTLs, or "cross-priming" (1). The most efficient APCs for cross-presentation and crosspriming are dendritic cells (DCs) (1, 2). DCs take up exogenous Ags and process them either via a cytosolic pathway dependent on TAP and proteasomes or via the endosomal pathway (which is independent of TAP and proteasomes) (3). However, the molecular machinery involved in cross-presentation has not been fully defined. For example, the molecules responsible for phagosome-cytosol export have not been identified (3). The physiological significance of cross-presentation is evident during defense against many infectious agents that do not infect APCs, and against tumors that do not originate from APCs; in both cases, cross-presentation is required to generate CTLs that are specific for the causative infectious agents and tumor Ags (2).
. In vivo cross-presentation and cross-priming were efficient, even without adjuvant; injection of mice with 3D8 scFv-OVA 250-264 induced cross-presentation of the CTL epitope by draining lymph node CD11c + B7.1 + MHC class II high DCs, elicited a CTL response, and suppressed the growth of tumors expressing the OVA epitope. This report shows that an anti-nucleic acid Ab is used to deliver exogenous Ag to the cross-presentation pathway and inhibit in vivo tumor growth. The Journal of Immunology, 2012, 189: 5755-5763.
A ntigens captured from the extracellular environment by APCs are processed and then presented on MHC class I molecules to CD8 + CTLs in a process called "cross-presentation," resulting in the stimulation of CTLs, or "cross-priming" (1) . The most efficient APCs for cross-presentation and crosspriming are dendritic cells (DCs) (1, 2) . DCs take up exogenous Ags and process them either via a cytosolic pathway dependent on TAP and proteasomes or via the endosomal pathway (which is independent of TAP and proteasomes) (3) . However, the molecular machinery involved in cross-presentation has not been fully defined. For example, the molecules responsible for phagosome-cytosol export have not been identified (3) . The physiological significance of cross-presentation is evident during defense against many infectious agents that do not infect APCs, and against tumors that do not originate from APCs; in both cases, cross-presentation is required to generate CTLs that are specific for the causative infectious agents and tumor Ags (2) .
Molecules capable of transferring exogenous Ag to the crosspresentation pathway have been examined in a number of studies to better understand the mechanisms underlying cross-presentation and to develop tumor vaccines that enhance CTL responses. For example, heat shock proteins (Hsp) such as Hsp70, Hsp90, and gp96 coupled to tumor cell peptides are internalized by APCs via a number of cellular receptors, including CD91, CD40, TLR2/4, LOX-1, and SR-A, whereupon they initiate tumor-specific CTL responses (4) (5) (6) (7) (8) (9) . Recent re-evaluation of the role of CD91 in gp96-mediated cross-presentation shows the importance of fluid phase-mediated, rather than receptor-mediated, uptake pathways and highlights the role of heparan sulfate proteoglycans (HSPGs) in surface binding of gp96 (10) . As for the cross-presentation pathway, the involvement of TAP-independent endosomal pathways was reported for Hsp90-peptide complexes (9) and for a CTL epitope coupled to penetratin, a cell-penetrating peptide derived from Drosophila antennapedia (11) . However, many of the steps involved in cross-presentation are still not fully understood.
Previously, we demonstrated that a 27-kDa recombinant nucleic acid-hydrolyzing single-chain Fv (3D8 scFv) was internalized by HeLa cells via a caveolae/lipid raft endocytosis pathway, and that HSPGs are the putative cell surface receptors that facilitate this (12, 13) . 3D8 scFv accumulates in the cytosol and is not translocated into late endosomes/lysosomes, the endoplasmic reticulum (ER), the Golgi, or the nucleus; the scFv finally induces apoptotic cell death via the degradation of cellular RNAs (12, 13) . Besides 3D8 scFv, endocytosis of some anti-DNA mAbs has been observed in non-APCs (14-16); however, their delivery of exogenous Ag to the cross-presentation pathway in APCs has not been shown.
The current study examined whether 3D8 scFv was able to access the cross-presentation pathway in murine DCs and crossprime CTLs. 3D8 scFv efficiently delivered a CTL epitope to the proteasome-dependent cross-presentation pathway in DCs. In addition, Ag delivered by 3D8 scFv induced cross-presentation and cross-priming in vivo. Furthermore, therapeutic vaccination using 3D8 scFv fused to a CTL epitope suppressed the growth of tumors expressing the CTL epitope.
Materials and Methods

Cells
The B16 murine melanoma cell line (H-2K b ) was obtained from Yonsei University (Seoul, Korea). The DC2. 4 (19) , was a generous gift from Dr. C.V. Harding (Case Western Reverse University, Cleveland, OH). B16 and CD8OVA1.3 cells were cultured in DMEM supplemented with 10% FCS and antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin). DC2.4 cells and MO5 cells were grown in RPMI 1640 medium supplemented with 10% FCS, 2 mM L-glutamine, 100 mM nonessential amino acids, 10 mM HEPES, 50 mM 2-ME, and antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin). MO5 culture medium was supplemented with G418 (1 mg/ml).
Production of scFv-OVA fusion proteins
The DNA fragments encoding a model H-2K b epitope, SIINFEKL (OVA 257-264 ) or SGLEQLESIINFEKL (OVA 250-264 ), were inserted into the pIg20-scFv bacterial expression vectors to generate 3D8-OVA 257-264 , 3D8-OVA 250-264 , or control HW6 OVA [250] [251] [252] [253] [254] [255] [256] [257] [258] [259] [260] [261] [262] [263] [264] (Fig. 1A) . Recombinant proteins containing a protein-A tag were purified from the supernatants of bacterial cultures, using IgG-Sepharose affinity chromatography (12) .
Isolation of CD11c
+ DCs from lymph nodes CD11c + dendritic cells were purified from the lymph nodes of C57BL/6 mice, using a MACS system (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's protocol. The purity of CD11c + cells was .80%, as assessed by flow cytometric analysis.
Cross-presentation assay
As previously described (19) , cross-presentation was examined by measuring IL-2 production by DC2. 4 5 cells per well) in the presence of scFv-OVA proteins for 24 h at 37˚C. IL-2 levels in the supernatants were measured with an ELISA kit (R&D Systems). In experiments using various inhibitory drugs, cross-presentation assays incorporated a DC2.4 cell fixation step. Briefly, MG-132 (20 mM), lactacystin (10 mM), polymyxin B (20 mg/ml), brefeldin A (5 mg/ml), chloroquine (100 mM), primaquine (50 mM), cycloheximide (5 mg/ml), or heparin (50 IU/ml) was added to the culture of DC2.4 cells for 30 min or 60 min prior to the addition of scFv-OVA proteins (5 mM) or the OVA 257-264 peptide (1 mM; Peptron; Daejeon, Korea). After 6 h of incubation at 37˚C, DC2.4 cells were washed three times with 2% FCS-PBS and fixed with 1% paraformaldehyde. CD8OVA1.3 T cells were then incubated with the fixed DC2.4 cells for 24 h at 37˚C, followed by measurement of IL-2 levels in the supernatant. To demonstrate the processing of scFv-OVA proteins, prefixed DC2.4 cells were incubated with scFv-OVA proteins for 6 h at 37˚C and then cocultured with CD8OVA1.3 T cells. All drugs were purchased from Sigma.
Confocal microscopy
To detect endocytosis of scFv-OVA proteins, cells (5 3 10 4 cells per well in a six-well plate) were pulsed with 5 mM proteins for 2 h at 37˚C, washed once with PBS, and further cultured for 2 h at 37˚C. Cells were then washed twice, fixed with 2% paraformaldehyde in PBS for 10 min, and permeabilized with PBS containing 0.1% saponin for 10 min. After blocking with 2% BSA-PBS for 1 h, the cells were labeled with 5 mg/ml rabbit IgG (Sigma), followed by TRITC-conjugated anti-rabbit IgG Ab (Sigma). Nuclei were stained with Hoechst 33342 (Invitrogen). When indicated, cells were pretreated with 50 IU/ml of heparin (Sigma) for 1 h at 37˚C and then pulsed with 5 mM 3D8-OVA 250-264 for 6 h at 37˚C in the presence of heparin. Cells were washed with 3% HCl (pH 2.5) for 3 min to remove surface-bound proteins and then fixed. Finally, cells were analyzed by confocal microscopy (Carl Zeiss LSM 710).
To detect the H-2K b -OVA 257-264 complex, cells were pulsed with 5 mM scFv proteins or 1 mM SIINFEKL peptide for 6 h at 37˚C and then labeled with biotin-anti-(H-2K b -OVA 257-264 ) Ab (clone 25-D1.16; eBioscience) followed by FITC-Streptavidin (Vector Laboratories).
To examine the translocation of 3D8-OVA 250-264 to the lysosomes, 3D8-OVA 250-264 was labeled using a Rhodamine Red-X protein labeling kit according to the manufacturer's instructions (Invitrogen). Cells were pulsed with Rhodamine-labeled 3D8-OVA 250-264 (3 mM) for 2 h at 37˚C and then chased for 0.5-6 h at 37˚C. LysoTracker Green (0.5 mM; Invitrogen) was added to the cells 30 min before each chase. 
Flow cytometry
MTT assay
Cell viability was analyzed using the colorimetric MTT assay, as previously described (20) . Briefly, cells were seeded at a density of 1 3 10 4 cells per well in 96-well plates and then cultured in the presence of scFv-OVA protein (10 mM) for 48 h at 37˚C. MTT solution (10 ml; 5 mg/ml in PBS) was then added to the wells. After 4 h, the culture medium was removed, and the formazan product formed in the cells was solubilized with 100 ml DMSO. Cell viability was determined by measuring the absorbance at 570 nm, using a microplate reader (Molecular Devices).
Cytosolic fractionation
Cytosolic fractions were prepared as previously described, with slight modifications (21) . In brief, cells (1 3 10 6 ) were pulsed with 5 mM 3D8-OVA 250-264 for 2 h, washed, and incubated for a further 3, 6, 12, or 24 h. Cells were harvested in Tris-EDTA buffer (500 ml per well), and the volume was adjusted to 2 ml per well by adding PBS. The suspended cells were divided into two equal halves (1 ml) to prepare total cell lysates and cytosolic fractions for each time point. The total cell lysate sample was washed and mixed with SDS sample buffer. The other sample was washed, homogenized in 200 ml fractionation buffer [10 mM Tris (hydroxymethyl) aminomethane/acetic acid, pH 7.0; 250 mM sucrose] using a 26-guage needle, and then centrifuged at 4000 3 g for 2 min to pellet the debris, plasma membranes, and nuclei. Subsequently, the supernatant was centrifuged at 400,000 3 g for 30 min to obtain a highly purified cytosolic fraction. All procedures were carried out at 4˚C or on ice.
Western blotting
3D8-OVA 250-264 was detected in the total cell lysate and cytosolic fractions by Western blotting with a rabbit anti-3D8 scFv Ab (13) , an HRPconjugated goat anti-rabbit IgG secondary Ab (Zymed Laboratories), and an ECL kit (Amersham Pharmacia Biotech). Poly(ADP-ribose) polymerase PARP cleavage was detected using rabbit anti-PARP (Cell Signaling Technology). Rabbit anti-b-actin (Cell Signaling Technology) was used to normalize protein loading.
Immunization of mice with 3D8-OVA 250-264
All animal experiments were performed using a protocol approved by the Ajou University Animal Care and Use Committee. To assess crosspresentation, seven-wk-old male C57BL/6 mice (H-2K b ) from DBL (Chungbuk, Korea) were inoculated s.c. (once in the right flank) with 3D8 scFv, 3D8-OVA 250-264 , HW6-OVA 250-264 , or full-length OVA protein at a dose of 50 mg per mouse. After 48 h, the right inguinal and left cervical lymph nodes were removed and subjected to a cross-presentation assay. To examine cross-priming by scFv-OVA, C57BL/6 mice were immunized (s.c. on the flank on days 1 and 7) with the indicated scFv-OVA or fulllength OVA proteins at a dose of 25 mg per mouse per injection. On day 15, splenocytes were isolated and used in a 51 Cr release assay.
Cr release assay
The CTL activity of the stimulated splenocyte population was assessed in a 51 Cr release assay, as described previously (22) . Briefly, splenocytes (1 3 , five mice per group were s.c. injected with 50 mg 3D8 scFv, 3D8-OVA 250-264 , HW6-OVA 250-264 , or full-length OVA protein (or with PBS as a negative control) daily in the nape of the neck for 3 consecutive days. Mice were sacrificed when tumor volume reached 4000-5000 mm 3 . Tumor volume was calculated as the following: longest diameter 3 shortest diameter 3 3/2 3 p/6.
Results
3D8-OVA fusion proteins are internalized by DC2.4 DCs
To monitor cross-presentation, 3D8 scFv and a control HW6 scFv specific for human TRAIL receptor 2 were tagged with a CTL epitope (Fig. 1A) . 3D8 scFv was tagged with the exact H-2K b epitope, SIINFEKL (OVA 257-264 ), or with a longer epitope, SGLEQLESIINFEKL (OVA 250-264 ), which contains the linker sequence "SGLEQLE" (preceding SIINFEKL) to augment Agprocessing efficiency (23) . The proteins were purified in soluble form from bacterial culture supernatants to avoid the need for cell lysis and refolding. Purity was .95% on SDS-PAGE gels (Fig.  1B) . The endotoxin level in these proteins was ,0.2 EU/mg, as determined by the Pyrosate test kit (Chester Springs, PA) (data not shown). The nucleic acid-binding and -hydrolyzing activity of 3D8 scFv (12, 13) was retained by the 3D8-OVA fusion proteins (Supplemental Fig. 1 ). The cell-penetrating activity of the 3D8-OVA fusion proteins and 3D8 scFv were comparable in MO5 and DC2.4 cells (Fig. 1C) . HW6 scFv did not internalize in either cell type. Internalization of 3D8-OVA 250-264 fusion proteins was inhibited by heparin, which is a representative heparan sulfate (Fig. 1D) . These results are compatible with our previous observations in HeLa cells and clearly show that 3D8-OVA proteins are internalized by both DC2.4 and MO5 cells.
3D8-OVA fusion proteins have little effect on the viability of DC2.4 DCs
Our previous work showed that 3D8 scFv (10 mM) induced HeLa cell death 48 h after internalization (13) . Therefore, to examine whether 3D8-OVA fusion proteins similarly induce cell death in DC2.4 cells, we analyzed PARP cleavage 48 h after treatment with 3D8-OVA fusion proteins, using MO5 cells as a control (Fig. 2A) . Increased PARP cleavage was induced in MO5 cells, but not in DC2.4 cells, by 3D8 scFv or 3D8-OVA, implying that cell death in MO5 cells, but not in DC2.4 cells, is induced by the uptake of 3D8 scFv or 3D8-OVA proteins. Concordantly, the MTT assay showed that cell viability decreased by 70% in MO5 cells treated with 3D8 scFv or 3D8-OVA proteins, but by ,10% in DC2.4 cells (Fig. 2B) . These results indicate that DC2.4 cells are much more tolerant to the cytotoxic activity of 3D8-OVA fusion proteins than are MO5 cells.
Cytosolic translocation and proteasome-involved degradation of 3D8-OVA fusion protein in DC2.4 DCs
To analyze the stability and cytosolic translocation of the 3D8-OVA fusion protein in DC2.4 cells, we chased 3D8-OVA 250-264 in total cell lysates and the cytosolic fractions of cells pulsed for 2 h with 3D8-OVA 250-264 . 3D8-OVA 250-264 was detected in the cytosolic fraction at 0 h chase, indicating the release of 3D8-OVA [250] [251] [252] [253] [254] [255] [256] [257] [258] [259] [260] [261] [262] [263] [264] (possibly from the endosomal compartment) into the cytosol during 2-h pulse. 3D8-OVA 250-264 was detected in the total cell lysates and in the cytosolic fractions during the early chase periods (0-6 h); however, it was difficult to detect 3D8-OVA 250-264 after 12 h (Fig. 3A) . In the presence of lactacystin, a proteasome inhibitor, the amount of 3D8-OVA 250-264 increased in the total cell lysate and cytosolic fraction after 6 h compared with that in the absence of lactacystin ( Fig. 3B; Supplemental Fig. 2 ). These findings indicate proteasome-involved degradation of 3D8-OVA 250-264 .
Next, we determined whether 3D8-OVA 250-264 localized in late endosomes and lysosomes. DC2.4 cells were pulsed for 2 h with rhodamine-3D8-OVA 250-264 and then chased by confocal microscopy. 3D8-OVA 250-264 did not localize in the late endosomes or lysosomes labeled with LysoTracker Green during the first 6 h of the chase (Fig. 3C) , suggesting that the late endosomes and lysosomes were unlikely to be involved in the degradation of 3D8-OVA 250-264 .
Cross-presentation of 3D8-OVA proteins by DC2.4 DCs occurs via a proteasome-dependent pathway To assess the cross-presentation of 3D8-OVA fusion proteins, we used a coculture system comprising DC2.4 cells expressing H-2K b and CD8OVA1.3 T hybridoma cells, which produce IL-2 upon recognition of the OVA 257--264 -H-2K b complex (19) . DC2.4 cells were cocultured with CD8OVA1.3 T hybridoma cells in the presence of 1-10 mM 3D8-OVA proteins or HW6-OVA proteins (Fig. 4A) for 12-48 h (Fig. 4B) . Both 3D8-OVA 250-264 and 3D8-OVA 257-264 induced IL-2 production in a time-and dosedependent manner. The control HW6 scFv and HW6-OVA 250-264 proteins did not stimulate IL-2 release. Because 3D8-OVA 250-264 induced higher IL-2 production than did 3D8-OVA 257-264 , the following experiments were performed using 3D8-OVA 250-264 . In the presence of heparin, which blocks internalization of 3D8-OVA 250-264 , IL-2 production stimulated by 3D8-OVA 250-264 was reduced by ∼70% ( Fig. 4C ; see Supplemental Table I for the actual amount of IL-2). To rule out the effect of possible LPS contamination of the 3D8-OVA 250-264 on IL-2 production, polymyxin B (which neutralizes LPS) (24) was added to the coculture. IL-2 production induced by 3D8-OVA 250-264 was unaffected (Fig. 4D) . To exclude the possible presence of free peptide in the 3D8-OVA 250-264 , IL-2 production was assessed in cultures stimulated with prefixed DC2.4 cells (Fig. 4E) . In contrast to the positive control OVA peptide (SIINFEKL), IL-2 production was not detected in cultures with prefixed DC2.4 cells in the presence of 3D8-OVA 250-264. These results indicate that cross-presentation of 3D8-OVA 250-264 occurs in DC2.4 cells.
To further demonstrate the cross-presentation of 3D8-OVA 250-264 , the H-2K b -OVA 257-264 complex was detected with an Ab specific for this complex and analyzed using flow cytometry (Fig. 4F ) and confocal microscopy (Fig. 4G) . H-2K b -OVA 257-264 complexes were detected on the surface of DC2.4 cells pulsed with 3D8-OVA for 6 h or with the SIINFEKL peptide (a positive control). These data demonstrate that 3D8 scFv can deliver Ag to the cross-presentation pathway in DC2.4 cells.
Exogenous Ags can be cross presented via the "cytosolic pathway" (proteasome/TAP dependent) or the "endosomal pathway" (proteasome/TAP independent) (1). Therefore, we examined the cross-presentation pathway for 3D8-OVA 250-264 in DC2.4 cells by inhibiting each of the pathways. DC2.4 cells were pulsed with 3D8-OVA 250-264, or with SIINFEKL as a control, in the presence of the indicated inhibitors. Cells were then fixed and used to stimulate CD8OVA1.3 T hybridoma cells ( Fig. 5 ; see Supplemental Table I for the actual amounts of IL-2). The proteasome inhibitor MG-132 (25) strongly inhibited IL-2 production under pulse conditions with 3D8-OVA 250-264 . By contrast, chloroquine, which neutralizes pH in the endosomes, or pepstatin A, an inhibitor of lysosomal proteolysis, did not suppress IL-2 production. These results agree with those presented in Fig. 3 and demonstrate that the 3D8-OVA 250-264 protein is mainly processed by proteasomes in the cytoplasm, independently of vacuolar acidification and protease activity. After processing by the proteasome in DCs, peptide loading onto MHC class I molecules takes place within the ER or within early endocytic compartments (1, 26) .
Cross-presentation via peptide loading in the ER is sensitive to brefeldin A, a drug that inhibits the export of proteins from the ER to the Golgi and induces retrograde protein transport from the Golgi to the ER (1). In contrast, cross-presentation via peptide loading within the early endocytic compartment is affected by primaquine, which interferes with the recycling of endosomes to the plasma membrane (24) . When DC2.4 cells were pretreated with primaquine and pulsed with 3D8-OVA 250-264 , IL-2 production was unchanged; however, it was suppressed by treatment with brefeldin A. These results suggest that peptides generated from 3D8-OVA 250-264 may be loaded onto MHC class I molecules in the ER in DC2.4 cells and not in early endocytic compartments. Treatment with cycloheximide, an inhibitor of protein biosynthesis, reduced IL-2 production under pulse conditions with 3D8-OVA 250-264 to a similar extent as brefeldin A, indicating that newly synthesized MHC class I molecules may be required for cross-presentation of 3D8-OVA 250-264 . The actual reduction in H-2K b expression levels by cells treated with primaquine, brefeldin A, and cycloheximide was confirmed by flow cytometry using an anti-H-2K b Ab (data not shown). Taken together, these results indicate that 3D8-OVA 250-264 may be presented by DC2.4 cells via the canonical cytosolic pathway, in which 3D8-OVA 250-264 is degraded by the proteasome and the peptides are loaded onto MHC class I molecules in the ER. 
In vivo cross-presentation and cross-priming of 3D8-OVA protein
To examine the in vivo cross-presentation of 3D8-OVA 250-264 , mice were immunized with 3D8-OVA 250-264 or a control protein such as 3D8 scFv, HW6-OVA 250-264 , or full-length OVA protein.
After 48 h, cells were isolated from the draining right inguinal lymph nodes and the nondraining cervical lymph nodes and incubated with CD8OVA1.3 T hybridoma cells for 24 h to monitor IL-2 production. When a positive control OVA peptide (SIIN-FEKL) was added to cocultures of CD8OVA1.3 T hybridoma cells and lymph node cells from PBS-injected mice, IL-2 production (∼2,000 pg/ml) was observed; however, no IL-2 was detected in cocultures with nondraining cervical lymph node cells, regardless of the injected proteins, or in the cocultures with draining inguinal lymph node cells from all mice, except those injected with 3D8 scFv 250-264 . Significant IL-2 levels (∼700 pg/ml) were detected in the cocultures with draining inguinal lymph node cells from mice injected with 3D8-OVA [250] [251] [252] [253] [254] [255] [256] [257] [258] [259] [260] [261] [262] [263] [264] (Fig. 6A) . These results demonstrate that 3D8-OVA 250-264 is cross presented in vivo. To identify cells cross presenting 3D8-OVA, CD11c + cells and CD11c 2 cells were isolated from the lymph nodes of mice immunized as described above, and then incubated with CD8OVA1.3 T hybridoma cells to monitor IL-2 production (Fig. 6B) . CD11c + cells from the draining inguinal lymph nodes of mice injected with 3D8-OVA 250-264 stimulated high levels of IL-2 production (∼1200 pg/ ml), but CD11c 2 cells stimulated only very low levels (∼60 pg/ ml). Concordantly, H-2K b -OVA 257-264 complexes were observed in .70% cells of inguinal lymph node CD11c 1 cells from mice immunized with 3D8-OVA 250-264 , but not from nondraining lymph node CD11c 1 cells of all mice. (Fig. 6C) . Furthermore, almost all CD11c + cells expressing H-2K b -OVA 257-264 complexes displayed MHC class II and B7.1 molecules on their surface (Fig.  6C, 6D, Supplemental Fig. 3 ). Some CD11c 2 cells from the inguinal lymph nodes of mice immunized with 3D8-OVA 250-264 displayed H-2K b -OVA 257-264 complexes and B7.1 (data not shown), which might account for the low level of IL-2 production shown in Fig. 6B . Taken together, these results indicate that 3D8-OVA induces CD11c + DC maturation in the absence of adjuvant and is cross presented by these cells.
To further support in vivo cross-presentation of 3D8-OVA 250-264 , C57BL/6 mice were immunized twice with 3D8-OVA 250-264 and splenocytes were isolated for the assay of OVA-specific CTL activity 7 d later. CTL activity was evaluated according to the percentage lysis of target cells in a 51 Cr release assay using B16 or MO5 cells as target cells. The MO5 cell line is an OVA-transfected subclone of a B16 melanoma. Splenocytes from mice injected with 3D8-OVA 250-264 showed a significant level of CTL activity against MO5 cells, but not against B16 cells (Fig. 7) . This finding indicates that 3D8-OVA 250-264 is cross presented in vivo, resulting in the generation of OVA-specific CTL. Further, it should be noted that cross-priming of 3D8-OVA 250-264 also occurred in the absence of adjuvant.
Finally, in vivo cross-presentation and cross-priming of 3D8-OVA 250-264 were investigated by analyzing the therapeutic effect of 3D8-OVA 250-264 against an established tumor. Because both 3D8-OVA 250-264 and 3D8 scFv were cytotoxic for MO5 in vitro (Fig. 2) , we reasoned that although both proteins might similarly inhibit B16 tumor growth, 3D8-OVA 250-264 might inhibit MO5 tumor growth to a greater extent than 3D8 scFv because only 3D8-OVA 250-264 could initiate OVA-specific CTL responses, which would attack MO5 cells expressing OVA, but not B16 cells. To verify this, we injected mice bearing a MO5 or B16 tumors of ∼50 mm 3 with 50 mg of 3D8 scFv, 3D8-OVA 250-264 , HW6-OVA 250-264 , or full-length OVA protein s.c. daily for 3 consecutive days and analyzed tumor growth (Fig. 8) . Tumor growth was not inhibited in the control mice injected with HW6-OVA 250-264 or full-length OVA protein compared with that in mice injected with PBS. However, tumor growth was inhibited by .50% in mice injected with 3D8 scFv or 3D8-OVA 250-264 compared with that in control mice. As expected, the inhibitory effect of 3D8-OVA 250-264 on B16 tumor growth was similar to that of 3D8 scFv; however, its effect on MO5 tumor growth was ∼1.5-fold greater than that of 3D8 scFv. These results indicate that 3D8-OVA 250-264 efficiently induces an OVA-specific CTL immune response after cross-presentation.
Discussion
In this study, we showed that 3D8 scFv can deliver Ag to the crosspresentation pathway both in vitro and in vivo. 3D8-OVA 250-264 was internalized by DC2.4 DCs and translocated to the cytosol, where OVA peptides were released from 3D8 scFv by the action of proteasomes. The released OVA peptides were loaded onto MHC class I molecules and presented on the surface of DC2.4 cells. Draining lymph node CD11c + DCs from mice cross presented OVA 48 h after injection of 3D8-OVA [250] [251] [252] [253] [254] [255] [256] [257] [258] [259] [260] [261] [262] [263] [264] . Ag targeting to the cross-presentation pathway in DCs has been studied using Ags coupled to carriers such as cell-penetrating peptides (CPPs) (27) (28) (29) , endocytosed Hsps (9, 30) , and Abs against DC-specific endocytic receptors, including DC-SIGN and DEC205 (26) . In particular, Ag targeting to the cross-presentation pathway in both murine and human DCs has been extensively studied by Steinman's group, using an anti-DEC205 Ab (31, 32) . However, crosspresentation of anti-nucleic acid Abs has not been demonstrated, even though their internalization has been observed in a variety of cells, such as kidney cell lines, an ovary cell line, and rat hepatoma cells (15, 16, 33) . Thus, our finding that 3D8 scFv is internalized by DCs, followed by cytosolic translocation and delivery of Ag to the cross-presentation pathway, may provide useful insights into the novel functions of anti-nucleic acid Abs.
Our results show that 3D8-OVA 250-264 was cross presented via the proteasome/TAP-dependent (sensitive to MG132) and ER peptide-loading (sensitive to brefeldin A) pathways. Whole OVA protein is cross presented via the proteasome/TAP-dependent early endosome peptide-loading pathway when internalized via a mannose receptor (CD206) (24, 34) . In this pathway, Ags are exported into the cytosol and processed by cytosolic proteasomes; the Ag-derived peptides are then reimported into the early endosomes via TAP in the endosomal membrane, ready for loading onto MHC class I molecules (this pathway is sensitive to primaquine treatment) (24, 34) . In contrast, cross-presentation of Hspassociated Ags, which are internalized through CD91, CD40, and scavenger receptors, can occur either via a TAP-and proteasomedependent cytosolic pathway, or a TAP-and proteasome-independent endosomal pathway, depending on the amino acid sequence of the peptide bound to the Hsp (9, 30, 35) . It remains to be clarified whether the cross-presentation pathway of 3D8 scFv is affected by the antigenic epitope sequences of its cargo.
The cell surface molecules involved in 3D8-OVA 250-264 internalization by DCs were not identified in this study. Strong candidates are HSPGs, which are involved in the endocytosis of 3D8 scFv by HeLa cells (13) and in the endocytosis of CPPs, which contain multiple cationic amino acid residues similar to 3D8 scFv (36) . It is reported that clustering of HSPGs triggers cytoskeletal remodeling and internalization pathways, and that HSPGs promote MHC class II-restricted Ag presentation by acting as coreceptors during Fcg-RII-mediated Ag presentation (37, 38) . However, in the current study, endocytosis of 3D8 scFv was not affected by treatment with heparinase III (which cleaves heparan sulfate of HSPGs; data not shown), despite the inhibition of 3D8 scFv endocytosis in the presence of heparin, a competitor of HSPGs. Therefore, identification of the molecules involved in endocytosis of 3D8 scFv by DCs requires further investigation.
We also demonstrated the in vivo antitumor effects of 3D8 scFv. In our previous work, 3D8 scFv caused hydrolysis of cellular RNAs, mainly in HeLa cells, resulting in cell death (13) . Concordantly, we observed reduced viability of MO5 cells after uptake of 3D8 scFv. Furthermore, 3D8 scFv inhibited the growth of pre-existing MO5 tumors when injected adjacent to the tumor. It is plausible that 3D8 scFv might be internalized into tumor cells and translocated to the cytosol, where it breaks down cellular RNAs, eventually triggering cell death. In vivo cross-presentation of 3D8-OVA 250-264 indirectly supported the in vivo uptake of 3D8 scFv by MO5 cells and its cytosolic translocation. We should note that the cytotoxic effects of 3D8 scFv differed between MO5 and DC2.4 DCs. Further studies are required to evaluate whether tumor cells preferentially internalize 3D8-OVA, and whether they are more susceptible to 3D8 scFv-mediated cytotoxicity than are normal cells.
Fusion of a CTL epitope increases the therapeutic effect of 3D8-scFv against tumors expressing the corresponding CTL epitope. 3D8-OVA 250-264 inhibited the growth of pre-established MO5 tumors significantly more than did 3D8 scFv, whereas the inhibitory effect of 3D8-OVA 250-264 on B16 tumor growth was similar to that of 3D8 scFv. This finding can be explained by the strong CTL response to OVA elicited by injection of 3D8-OVA 250-264 . Accumulating evidence shows the efficacy of prophylactic tumor vaccines incorporating Hsp70 (39), CPPs (27, 40) , and a2M* (41); however, little evidence exists for the efficacy of therapeutic vaccines. Moreover, CPPs require adjuvant to generate an effective antitumor response. Generally, vaccination with protein Ags in soluble form is not sufficient to induce strong CTL responses, even if Ags are cross presented by DCs. The use of adjuvants is usually necessary to stimulate innate immunity via TLR ligands expressed by DCs and to generate the immunogenic environment required for CTL induction (24, 42, 43) . Peptide epitopes incorporated into CPP carriers were able to elicit strong Ag-specific CTL responses when administrated along with adjuvants such as CpG and OK432 (27, 28, 44) . However, some protein carriers, such as a2M*, Hsp70, and Hsp90, possess intrinsic innate immunity-stimulating ability. Ags incorporated with the a2M* protein, which is internalized via CD91, were able to elicit antitumor activity in the absence of an adjuvant because a2M* itself can function as an adjuvant to stimulate innate immunity (41) . In another study, an Hsp70-coupled peptide cross primed peptidespecific T cells without adjuvant in mice and activated TLR4-deficient DCs to release proinflammatory cytokines (45) . Hsp90 efficiently induced peptide-specific CTL responses in mice, which were comparable to those induced by immunization with a peptide emulsion in CFA (9) . We found that 3D8-OVA 250-264 elicits the maturation of draining lymph node DCs (Fig. 6C, 6D) and Agspecific CTL responses in vivo in the absence of adjuvant and enhances the antitumor effects of 3D8 scFv. Unexpectedly 3D8 scFv did not induce maturation (B7.1 expression) on DCs. We speculate that 3D8-OVA 250-264 may indirectly induce B7.1 expression through interaction with OVA-specific T cells. Our findings raise the question of how 3D8 scFv plays a role as an adjuvant.
In conclusion, this report shows cross-presentation of an antinucleic acid scFv (3D8 scFv) and its associated in vivo therapeutic antitumor effects. As it does not require an adjuvant to elicit a CTL response, a 3D8 scFv-based vaccine strategy would be worthy of further investigation for use as a cancer immunotherapeutic.
